Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development
MWN-AI** Summary
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), known for its innovative treatments for muscle diseases, has made significant leadership changes to enhance its late-stage clinical development efforts. The company is welcoming Robert Blaustein, M.D., Ph.D., as the new Chief Development Officer (CDO) and has promoted Behrad Derakhshan, Ph.D., from Chief Business Officer to Chief Operating Officer (COO).
Dr. Blaustein brings over 15 years of experience in cardiovascular drug development from his previous position at Merck, where he led late-phase development efforts, including the successful Phase 3 VICTORIA trial for the heart failure treatment vericiguat. His expertise will be instrumental as Edgewise advances its late-stage program for EDG-7500, a promising cardiac sarcomere modulator currently in Phase 2 trials, alongside its cardiovascular and cardiometabolic pipeline. Dr. Kevin Koch, President and CEO of Edgewise, expressed confidence that these appointments will position the company for future commercialization of its novel therapeutics.
Dr. Derakhshan, who joined Edgewise in 2020, has been pivotal in the company’s growth trajectory and will now focus on operational readiness as Edgewise aims to transition into a commercial-ready biopharmaceutical firm. His previous accomplishments include leading the strategic planning and fundraising efforts that supported the company's IPO and subsequent funding rounds.
The leadership changes reflect Edgewise’s commitment to advancing its innovative therapies for muscle diseases and cardiovascular conditions. The firm also continues to progress with its clinical programs, having recently reported positive topline data for EDG-7500 in both healthy subjects and patients with obstructive hypertrophic cardiomyopathy (HCM). With these changes, Edgewise aims to further its mission of improving the lives of patients with serious muscle diseases.
MWN-AI** Analysis
Edgewise Therapeutics, Inc. (Nasdaq: EWTX) has made significant strides in enhancing its leadership team, which is likely to strengthen its late-stage clinical development efforts and positively influence market perception. The appointment of Robert Blaustein, M.D., Ph.D., as Chief Development Officer (CDO) brings a wealth of experience in cardiovascular drug development, notably leading the successful Phase 3 VICTORIA trial. His expertise in guiding novel drug candidates through late-stage trials may accelerate the development timeline for EDG-7500, a promising cardiac sarcomere modulator currently in Phase 2.
Additionally, the promotion of Behrad Derakhshan, Ph.D., to Chief Operating Officer (COO) reflects the company’s strategic focus on operational readiness as it approaches pivotal milestones in both its muscular dystrophy and cardiovascular programs. Dr. Derakhshan has demonstrated operational acumen and vision, which will be crucial as Edgewise transitions toward potential commercialization.
Given the positive topline data previously reported for EDG-7500 and the management changes, Edgewise appears well-positioned for future success. Investors should take note of the company’s shift toward late-stage development, which could result in valuation uplifts as clinical programs progress. The leadership team’s collective experience may not only bolster confidence in existing pipelines but also open doors for strategic partnerships or collaborations, enhancing the company’s growth trajectory.
Market participants should monitor Edgewise’s developments closely, particularly clinical trial results, as successful outcomes could lead to significant stock rallies. There remains a favorable risk-reward balance, but investors should be cognizant of the inherent volatility in biopharmaceutical stocks and position accordingly. Overall, Edgewise Therapeutics represents a compelling opportunity, particularly as it seeks to transform innovative therapies into real-world solutions for patients with muscular dystrophies and cardiac conditions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Robert Blaustein, M.D., Ph.D. appointed as Chief Development Officer (CDO) -
- Behrad Derakhshan, Ph.D. promoted to Chief Operating Officer (COO) -
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced key changes to its executive team that will strengthen its leadership and sharpen the Company’s focus on late-stage clinical development. These changes include the addition of Robert Blaustein, M.D., Ph.D., joining the Company as Chief Development Officer and the promotion of Behrad Derakhshan, Ph.D. from Chief Business Officer to Chief Operating Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122879951/en/
Robert Blaustein, M.D., Ph.D., Chief Development Officer, Edgewise Therapeutics (Photo: Business Wire)
"These leadership changes signify our organization's progression into late-stage clinical development, setting the stage for the future commercialization of our novel therapeutics," said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise Therapeutics. "As we welcome Rob, it’s an exciting time for the Company, and we are fortunate to have a highly experienced executive team guiding us forward."
Robert Blaustein, M.D., Ph.D., joins the Company as Chief Development Officer, responsible for leading EDG-7500, a novel cardiac sarcomere modulator in Phase 2 development, as well as the cardiovascular and cardiometabolic pipeline. With significant depth of experience in cardiovascular drug development, Dr. Blaustein joins from Merck where he was most recently Associate Vice President and the Atherosclerosis Section Head in the Atherosclerosis and Metabolism Clinical Research Department, leading all late phase development efforts in this area. During his 15+ years at Merck, Dr. Blaustein contributed to clinical programs across a range of cardiovascular targets and led clinical development in the atherosclerosis and heart failure spaces. Importantly, he led the vericiguat development team through the completion of the Phase 3 VICTORIA heart failure trial, subsequent regulatory filing and global approval of vericiguat for the treatment of patients with worsening heart failure, a collaborative effort with Bayer AG. Dr. Blaustein obtained his undergraduate degree in mathematics from Wesleyan University. His post-graduate training included medical residency at Brigham and Women’s Hospital, cardiology fellowship at Massachusetts General Hospital, and an HHMI post-doctoral fellowship in the Biochemistry Department at Brandeis University. He subsequently served on the faculty of Tufts Medical Center prior to joining Merck.
Dr. Semigran, current CDO, will depart from the Company and will serve as a clinical advisor for a period to ensure a smooth transition. “On behalf of the Board of Directors and the entire Edgewise organization, I want to thank Marc for his leadership and contributions to our cardiovascular program,” said Dr. Koch. "Marc played a prominent role in successfully advancing EDG-7500 in the clinic.” Most recently the Company reported positive topline data of EDG-7500 in the Phase 1 trial in healthy subjects and from the single-dose arm (part A) of the Phase 2 CIRRUS-HCM trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Further, the Company opened and began enrolling the 28-day arms (parts B and C) and the 12-week open label extension (part D) of the CIRRUS-HCM trial in patients with obstructive HCM and non-obstructive HCM. There are no changes in previously described milestone timelines for the Company’s cardiovascular program.
Behrad Derakhshan, Ph.D., joined Edgewise in 2020 as Chief Business Officer, leading the Company’s efforts in strategic planning, business development, capital formation, investor relations, corporate communications and commercial planning. He was instrumental through the Company’s highly successful initial public offering, played a key role securing several additional funding rounds and driving the strategic direction of the organization. Dr. Derakhshan’s leadership and vision have been instrumental in fueling Edgewise’s growth and success to date. As COO, Dr. Derakhshan will be responsible for enabling the operational readiness of the organization as the Company approaches significant milestones in the muscular dystrophy and cardiovascular programs, moving toward a commercial-ready biopharmaceutical company.
These changes to the Edgewise executive team are effective immediately.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn , X , Facebook and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20250122879951/en/
Edgewise Contacts
Investors:
Michael Carruthers, Chief Financial Officer
ir@edgewisetx.com
Media:
Maureen Franco, VP Corporate Communications
media@edgewisetx.com
FAQ**
How will the appointment of Robert Blaustein, M.D., Ph.D. as Chief Development Officer impact the late-stage clinical development of Edgewise Therapeutics Inc. EWTX’s cardiac and cardiometabolic pipeline?
What specific milestones does Edgewise Therapeutics Inc. EWTX aim to achieve under Behrad Derakhshan, Ph.D.’s leadership as Chief Operating Officer?
In what ways are the recent leadership changes at Edgewise Therapeutics Inc. EWTX expected to improve operational readiness as the company moves towards commercialization of its therapeutics?
What lessons from Dr. Blaustein's previous experience at Merck will be applied to the development of EDG-7500 at Edgewise Therapeutics Inc. EWTX?
**MWN-AI FAQ is based on asking OpenAI questions about Edgewise Therapeutics Inc. (NASDAQ: EWTX).
NASDAQ: EWTX
EWTX Trading
15.75% G/L:
$39.055 Last:
2,691,761 Volume:
$40.60 Open:
